Short description
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Description
Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.
Last funding
Noway Youcantaccess
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Cambridge, Massachusetts, United States, North America
Founded on
January 1, 2020
Exited on
January 7, 2022
Went public on
January 7, 2022
Stock symbol
VIGL
Non-profit?
No
Acquired?
No
Employees count
51-100
Revenue range
$56378 - 90123
Sign in for full access
Investors
Noaccess, Cannot Access, No Way, Blurry Noaccess, Nopepepe, Nopepepe, Absolutely Noaccess, Absolutely Noaccess, Uh Ohhhh, No Way, Nopepepe, Blurry Noaccess, Blurry Noaccess, Cannot Access
Sign in for full access
Founders
Ivana Magovčević-Liebisch